Somewhat Positive Press Coverage Somewhat Unlikely to Affect Anika Therapeutics (ANIK) Stock Price
Headlines about Anika Therapeutics (NASDAQ:ANIK) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anika Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.173646493962 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Viscosupplementation Market By Product, By Region And Segment Forecasts, 2014 – 2025 (prnewswire.com)
- Sports medicine market in global to be worth USD 32,199.3 million by 2024 explored in latest research (whatech.com)
- Aesthetics Combination Therapy Market Projected to Rake US$ 3.69 Bn by 2024 (sbwire.com)
- What strategies to adopt for growth in the Europe spirometer market ? (whatech.com)
Anika Therapeutics (ANIK) opened at 56.69 on Friday. Anika Therapeutics has a 12-month low of $41.38 and a 12-month high of $57.93. The stock has a 50 day moving average price of $53.44 and a 200 day moving average price of $47.83. The company has a market capitalization of $830.96 million, a price-to-earnings ratio of 25.18 and a beta of 1.65.
Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.32. The company had revenue of $33.50 million during the quarter, compared to the consensus estimate of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The firm’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.57 earnings per share. On average, analysts expect that Anika Therapeutics will post $2.20 EPS for the current year.
Several research firms have recently issued reports on ANIK. Zacks Investment Research raised Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th.
In related news, CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the completion of the sale, the chief executive officer now owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Charles H. Sherwood sold 14,201 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total transaction of $710,476.03. Following the sale, the chief executive officer now directly owns 246,740 shares of the company’s stock, valued at approximately $12,344,402.20. The disclosure for this sale can be found here. 6.57% of the stock is owned by company insiders.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.